[Financial Performance](index=4&type=section&id=Financial%20Performance) Net revenues decreased in Q4 and full-year 2022 due to increased allowances, but significant cost reductions substantially lowered operating losses, leading to debt extinguishment and a $36.1 million cash balance - The company became **debt-free** after extinguishing all obligations with HCR through the sale of Movantik® rights[7](index=7&type=chunk)[8](index=8&type=chunk)[29](index=29&type=chunk) - A key focus on cost reduction successfully lowered operating losses significantly in 2022 compared to 2021[7](index=7&type=chunk)[15](index=15&type=chunk)[24](index=24&type=chunk) - The cash balance was **$36.1 million** as of December 31, 2022[7](index=7&type=chunk)[17](index=17&type=chunk) [Q4 2022 Financial Results](index=4&type=section&id=Financial%20results%20for%20the%20three%20months%20ended%20December%2031%2C%202022%20%28Unaudited%29) Q4 2022 saw net revenues decrease to $12.8 million due to higher allowances, while operating loss significantly improved to $9.9 million from $20.7 million due to expense reductions Q4 2022 vs. Q4 2021 Financials (in millions USD) | Metric | Q4 2022 | Q4 2021 | Change Driver | | :--- | :--- | :--- | :--- | | Net Revenues | $12.8 | $22.1 | Increased gross-to-net allowances | | Operating Loss | $9.9 | $20.7 | Cost-reduction measures | | R&D Expenses | $1.1 | $5.9 | Optimization and completion of COVID trials | | SG&A Expenses | $13.0 | $17.6 | Ongoing cost-reduction measures | | Net Cash Used in Operating Activities | $2.4 | $14.9 | Reduction in operating expenses | - The decrease in net revenues occurred despite prescription growth for Talicia and Movantik, primarily due to increased gross-to-net allowances[10](index=10&type=chunk) [Full-Year 2022 Financial Results](index=5&type=section&id=Financial%20results%20for%20the%2012%20months%20ended%20December%2031%2C%202022) Full-year 2022 net revenues decreased to $61.8 million due to Movantik allowances, but operating loss significantly reduced to $42.8 million from $81.1 million due to effective cost controls Full-Year 2022 vs. Full-Year 2021 Financials (in millions USD) | Metric | FY 2022 | FY 2021 | Change Driver | | :--- | :--- | :--- | :--- | | Net Revenues | $61.8 | $85.8 | Increased gross-to-net allowances (Movantik) | | Operating Loss | $42.8 | $81.1 | Reduction in operating expenses | | R&D Expenses | $7.3 | $29.5 | Optimization and completion of COVID trials | | SG&A Expenses | $64.0 | $88.0 | Cost-control measures, reduced salesforce | | Net Cash Used in Operating Activities | $29.2 | $65.0 | Lower operating loss and expenses | - The full-year revenue decline was primarily attributed to increased gross-to-net allowances, mainly related to Movantik[18](index=18&type=chunk) [Consolidated Financial Statements](index=12&type=section&id=Consolidated%20Financial%20Statements) Consolidated financial statements detail 2022 comprehensive loss, financial position, and cash flows, showing a $71.7 million net loss, $158.9 million in total assets, and a $48.4 million capital deficiency Consolidated Statement of Comprehensive Loss (in thousands USD) | Metric | 2022 | 2021 | | :--- | :--- | :--- | | Net Revenues | 61,800 | 85,757 | | Gross Profit | 28,463 | 36,351 | | Operating Loss | (42,844) | (81,135) | | Loss and Comprehensive Loss | (71,669) | (97,744) | | Loss Per Share (basic and diluted) | $0.12 | $0.21 | Consolidated Statement of Financial Position (in thousands USD) | Metric | Dec 31, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | Total Assets | 158,870 | 181,188 | | Total Liabilities | 207,270 | 172,313 | | Total Equity (Capital Deficiency) | (48,400) | 8,875 | Consolidated Statement of Cash Flows (in thousands USD) | Metric | 2022 | 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | (29,185) | (65,047) | | Net cash (used in) provided by investing activities | 8,302 | (8,140) | | Net cash provided by financing activities | 11,453 | 73,462 | [Operational and Business Highlights](index=6&type=section&id=Operational%20and%20Business%20Highlights) Strategic highlights include debt extinguishment via Movantik sale, Nasdaq compliance, and capital raises, alongside strong Talicia® growth and R&D advancements for Opaganib and RHB-102 [Business Updates](index=6&type=section&id=Business%20updates) Key business updates include debt extinguishment via Movantik sale, regaining Nasdaq compliance, and successful capital raises through direct and public offerings - All debt obligations with HealthCare Royalty (HCR) were extinguished by transferring Movantik® rights, with RedHill providing up to 12 months of paid transition services[29](index=29&type=chunk) - Compliance with Nasdaq's minimum bid price requirement was regained following an American Depositary Shares (ADS) ratio change[27](index=27&type=chunk) - A **$6 million** registered direct offering closed in April 2023, and an approximately **$8.0 million** underwritten public offering closed in December 2022[28](index=28&type=chunk)[30](index=30&type=chunk) [Commercial Highlights](index=7&type=section&id=Commercial%20Highlights) Talicia® showed strong commercial growth with a 57% prescription increase and a new warranty, Aemcolo® gained extended exclusivity, and Movantik® rights were transferred to extinguish debt - Talicia® achieved **57% year-over-year prescription growth** and is projected to be the most prescribed branded H. pylori therapy in the U.S. in 2023[34](index=34&type=chunk) - A first-of-its-kind warranty program for Talicia® commits to reimbursing patient out-of-pocket costs if treatment is ineffective[8](index=8&type=chunk)[34](index=34&type=chunk) - Aemcolo® received an additional **five years of FDA exclusivity**, extending its regulatory protection through 2028[35](index=35&type=chunk) - Movantik® ownership was transferred to an HCR affiliate on February 6, 2023, extinguishing all of RedHill's debt[39](index=39&type=chunk) [R&D Pipeline Highlights](index=8&type=section&id=R%26D%20Highlights) R&D pipeline advanced with Opaganib selected by NIH for ARS and FDA guidance, RHB-102 planned for UK oncology application, and progress for RHB-107 and RHB-204 - Opaganib was selected by the NIH's RNCP for development as a potential treatment for Acute Radiation Syndrome (ARS)[7](index=7&type=chunk)[39](index=39&type=chunk) - The FDA provided guidance for opaganib's ARS development under the Animal Rule, utilizing animal efficacy studies and offering potential for a Priority Review Voucher[7](index=7&type=chunk)[39](index=39&type=chunk) - Following a positive pre-MAA meeting with the UK's MHRA, the company plans to submit a Marketing Authorisation Application for RHB-102 (Bekinda) for oncology support[7](index=7&type=chunk)[42](index=42&type=chunk) - RHB-204 (for NTM disease) received a Notice of Allowance for a U.S. patent, with protection expected through **2041**[42](index=42&type=chunk) - RHB-107 (upamostat) showed a **100% reduction in hospitalization** due to COVID-19 in a Phase 2 study[42](index=42&type=chunk)

Financial Performance - Net revenues for Q2 2022 were $18.346 million, a decrease of 14.3% compared to $21.502 million in Q2 2021[6] - Gross profit for the first half of 2022 was $16.162 million, down 23.8% from $21.234 million in the same period of 2021[6] - The company reported a comprehensive loss of $11.711 million for Q2 2022, a decrease of 59.8% from $29.121 million in Q2 2021[6] - The loss per ordinary share for the first half of 2022 was $0.06, compared to $0.12 in the same period of 2021[6] - Movantik® revenues decreased to $16.125 million for the three months ended June 30, 2022, down from $19.212 million in the same period of 2021, representing a decline of approximately 11%[58] - The company reported total net revenues of $18.346 million for the three months ended June 30, 2022, compared to $21.502 million for the same period in 2021, reflecting a decrease of about 14%[58] - The company recorded a consolidated comprehensive loss of $11.711 million for the three months ended June 30, 2022, compared to a loss of $29.121 million in the same period of 2021, showing an improvement of about 60%[65] - The financial expense of $2.552 million for the three months ended June 30, 2022, compared to $4.235 million in the same period of 2021, reflecting a decrease of approximately 40%[65] Expenses and Cost Management - Research and development expenses significantly decreased to $1.472 million in Q2 2022 from $10.328 million in Q2 2021, reflecting a reduction of 85.7%[6] - The operating loss for the first half of 2022 was $25.788 million, compared to $43.038 million in the first half of 2021, indicating a 40.0% improvement[6] Assets and Liabilities - Total assets as of June 30, 2022, were $167.967 million, down from $181.188 million at the end of 2021[9] - Current liabilities increased to $166.415 million as of June 30, 2022, compared to $81.470 million at the end of 2021[9] - The allowance for deductions from revenues increased to $39.223 million as of June 30, 2022, from $30.711 million as of January 1, 2022, indicating a rise of approximately 28%[49] Cash Flow and Financing - Cash and cash equivalents at the end of Q2 2022 were $26.988 million, down from $29.474 million at the end of 2021[9] - The company raised $15.508 million from the issuance of ordinary shares and warrants in Q2 2022, compared to $273,000 in Q2 2021[16] - The company sold 836,476 American Depositary Shares (ADSs) under its "at-the-market" equity offering program at an average price of $2.18 per ADS, resulting in net proceeds of approximately $1.8 million[42] - The company entered into a definitive agreement with a single investor, issuing 10,563,380 ADSs and granting warrants to purchase up to 13,204,225 ADSs for a total net consideration of $14.4 million[45] - HCRM exercised its rights to control RedHill Inc.'s account, transferring $16 million as minimum cash required under the Credit Agreement[70] - The $16 million Funds are classified as Restricted Cash in the financial position statements as of June 30[70] Strategic Initiatives and Agreements - An exclusive license agreement with Gaelan Medical Trade LLC for Talicia in the UAE resulted in an upfront payment of $2 million, with additional milestone payments and tiered royalties up to mid-teens on net sales[42] - The company recognized $2 million in revenue from the license of Talicia IP rights and manufacturing services during the six months ended June 30, 2022[41] Business Challenges and Outlook - Management expects to incur additional losses as it focuses on advancing the development of its therapeutic candidates and commercial operations, leading to negative cash flows from operating activities[19] - The COVID-19 pandemic has materially impacted the company's commercial activities, including launch sales and marketing for Talicia and sales of Aemcolo[27] - The company has sufficient supply on hand to meet U.S. commercial demand and clinical study needs despite the challenges posed by the COVID-19 pandemic[26] - The company has classified its borrowing as a current liability due to uncertainty regarding compliance with covenants under the Credit Agreement, raising substantial doubt about its ability to continue as a going concern[24] - RedHill Inc. is required to maintain minimum net sales of $75 million for the trailing four fiscal quarters ending June 30, 2022, and September 30, 2022, increasing to $90 million each fiscal quarter thereafter[11] Legal Matters - RedHill Inc. filed a lawsuit against Kukbo for defaulting on a $5 million payment under the Subscription Agreement[70] - An additional $1.5 million is due from Kukbo under the Exclusive License Agreement[70] - The lawsuit against Kukbo is being translated into Korean for filing in South Korea[70] - A summary judgment against Kukbo is expected to be entered in the United States within several weeks[70] Discussions and Negotiations - The company has entered discussions with HCR Collateral Management regarding a consensual business solution and is evaluating strategic alternatives to satisfy its outstanding obligations under the Credit Agreement[25] - The company is engaged in discussions with HCRM regarding alleged events of default under the Credit Agreement, while continuing to operate its business as usual[66]

Financial Data and Key Metrics Changes - RedHill reported net revenues of $18.2 million in Q1 2022, down from $22.1 million in Q4 2021, attributed to typical cyclical trends in Movantik sales [72] - Gross profit was $10.2 million in Q1 2022, representing a 56% gross margin, expected to improve as Talicia prescriptions grow [73] - Cash used in operating activities decreased by over 70% to approximately $4 million compared to approximately $15 million in Q4 2021, indicating a clear path towards financial independence [71] Business Line Data and Key Metrics Changes - Movantik achieved an 8.6% increase in prescription volume compared to Q1 2021, maintaining nearly 74% market share in the PAMORA class [27][35] - Talicia's prescription volume grew by 12.8% over Q4 2021 and 80% compared to Q1 2021, establishing it as the most prescribed branded H. pylori therapy in the U.S. [24][37] - The company achieved record quarterly prescription volume for both Movantik and Talicia in Q1 2022, with positive momentum continuing into Q2 [26][36] Market Data and Key Metrics Changes - Talicia became available to 14 million Medi-Cal beneficiaries as a preferred brand with no restrictions, enhancing its market access [38] - The company expects further prescription volume lift from improved payer coverage and recognition of Talicia's clinical benefits [40] Company Strategy and Development Direction - RedHill is focused on achieving earlier profitability, targeting positive cash from operations to start during the second half of 2022, with a comprehensive cost reduction plan expected to generate approximately $50 million in savings over the next 18 months [8][15] - The company is exploring potential acquisitions of revenue-generating synergistic products to expedite cash generation [12] - RedHill is committed to advancing its COVID-19 programs, opaganib and RHB-107, through external funding sources, emphasizing the need for oral therapeutics in the ongoing pandemic [19][50] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the current market reality but expressed confidence in the company's ability to achieve financial stability and growth [8][11] - The management highlighted the importance of cash preservation and generating cash flow as a priority, with a clear goal of achieving breakeven during the second half of the year [95] Other Important Information - The company has streamlined its U.S. commercial team workforce by approximately one-third as part of its cost reduction plan [9] - RedHill's R&D expenses decreased to $3.1 million in Q1 2022 from $5.9 million in Q4 2021, reflecting ongoing optimization of R&D costs [73] Q&A Session Summary Question: Impact of the reduction of the commercial team on overall sales - Management indicated that territories would be covered by remaining representatives and that a comprehensive analysis was conducted to optimize commercial operations [79][84] Question: Expected timeline for achieving $50 million in OpEx savings - Management provided a detailed plan indicating that savings would be realized over the next six quarters [86] Question: Competitive landscape for Talicia following a competitor's FDA approval - Management expressed confidence in Talicia's efficacy, particularly in addressing clarithromycin resistance, which is a significant issue in H. pylori treatment [91] Question: Cash flow positive from operations definition - Management clarified that cash flow positive includes all G&A and selling expenses, excluding stock compensation [106] Question: Current cash runway and operational profitability timeline - Management confirmed confidence in cash runway for the next 12 months and beyond, with plans to achieve operational profitability in the second half of the year [112]

RedHill Biopharma Ltd. (NASDAQ:RDHL) Q4 2021 Earnings Conference Call March 17, 2022 8:30 AM ET Company Participants Alexandra Okmian Sanderovich - Senior Business Development and Investor Relations Manager Dror Ben-Asher - Chief Executive Officer Guy Goldberg - Chief Business Officer Gilead Raday - Chief Operating Officer Rob Jackson - Senior VP, Sales & Marketing Micha Ben Chorin - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald David Hoang - SMBC Boobalan Pachaiyap ...

COVID-19 Treatment Development - The company is pursuing the study of opaganib and RHB-107 as potential treatments for COVID-19, but there is a high level of uncertainty regarding their safety and efficacy [23]. - The biotechnology sector is highly competitive, with numerous companies developing COVID-19 treatments and vaccines, which may limit the commercial opportunity for the company's therapeutic candidates [27]. - The company has entered into collaborations with leading manufacturers to expand manufacturing capacity for opaganib in preparation for potential emergency use applications [34]. - The ongoing COVID-19 pandemic has adversely affected the company's business, revenues, and results of operations, particularly impacting sales of commercial products due to decreased in-clinic patient visits [39]. - The company has experienced slow enrollment in clinical trials, such as the Phase 3 study with RHB-204, which has delayed progress [39]. - The company may face difficulties in scaling up manufacturing processes for opaganib and RHB-107, which could impact the supply for clinical trials and commercial use [23]. - The company may need to devote significant resources to expand sales and marketing activities if COVID-19 therapeutic candidates are approved for marketing [30]. - The continuation of the COVID-19 pandemic could materially disrupt the company's business and operations, affecting sales and financial obligations [43]. Financial Performance and Projections - The company experienced net losses of approximately $97.7 million in 2021, $76.2 million in 2020, and $42.3 million in 2019, with an accumulated deficit of approximately $367.9 million as of December 31, 2021 [48]. - As of December 31, 2021, the company had cash, cash equivalents, short-term investments, and restricted cash of approximately $54.2 million, up from $46.0 million as of December 31, 2020 [51]. - The company plans to fund future operations through commercialization of products like Movantik®, Talicia®, and Aemcolo®, as well as out-licensing therapeutic candidates and raising additional capital [52]. - The company has only started to record meaningful net revenues since the end of 2020 and is not yet profitable [54]. - The company has a history of operating losses and may continue to incur significant losses in the coming years [45]. - The company may need to raise additional capital to achieve strategic objectives and execute business plans, as current working capital is insufficient [50]. Regulatory and Compliance Risks - The company faces risks related to regulatory compliance and potential enforcement actions that could adversely affect its reputation and financial condition [61]. - Regulatory approvals for commercial products are subject to ongoing review, and failure to comply with regulations could lead to loss of approvals and adverse effects on the company's financial condition [160]. - The FDA approval for Aemcolo® is contingent upon completing additional studies, which may affect its market acceptance and profitability [76][80]. - The FDA may require additional clinical trials or studies for therapeutic candidates, which can lead to increased costs and delays in obtaining marketing clearance [171]. - The company is subject to extensive governmental laws and regulations regarding the development and commercialization of its products [142]. Market Competition and Challenges - The company faces intense competition for qualified personnel, which may impact its ability to attract and retain key employees necessary for its operations [135]. - The company competes with other entities for in-license or acquisition opportunities, which may hinder its growth if it cannot secure favorable terms [127]. - Movantik® competes with other approved PAMORA drugs and several branded prescription therapies for treating opioid-induced constipation (OIC) [206]. - Talicia® competes with both branded and generic therapies for H. pylori treatment, including a new Vonoprazan-based combination treatment under development by Phathom Pharmaceuticals [207]. - The company faces competition from pharmaceutical and biotechnology firms that have greater R&D capabilities and resources, which intensifies market competition [209]. Manufacturing and Supply Chain Issues - Supply chain disruptions due to the COVID-19 pandemic have resulted in shipping delays and increased costs, which could adversely affect the company's financial condition and results of operations [44]. - The reliance on third-party manufacturers for commercial products poses risks, including potential supply interruptions and quality assurance issues [114]. - The company is in the process of transitioning the manufacture of Movantik® from AstraZeneca to other third parties, which must be completed successfully to meet supply requirements [114]. - The company anticipates continued reliance on third-party manufacturers for its therapeutic candidates, which may affect the timely production of commercial quantities [121]. - The company may incur higher than expected costs in the commercialization of products, potentially leading to a reduction or termination of commercial activities [104]. Product Development and Approval - Most therapeutic candidates are in late-stage clinical development and will require successful additional clinical trials for regulatory approvals [48]. - The company has six therapeutic candidates in late-clinical stage development, aiming for FDA or foreign regulatory approvals [142]. - The company must complete two pediatric postmarketing studies for Aemcolo® by June 2025 and January 2025, respectively, to retain FDA approval, with potential penalties for non-compliance [78][81]. - The company has received orphan drug designation for RHB-104 for Crohn's disease, which provides financial incentives and potential exclusivity for seven years upon FDA approval [181]. - The company is advancing the development of a companion diagnostic for MAP detection in Crohn's disease patients, but the timeline for availability remains uncertain [174]. Human Resources and Operational Challenges - The company has experienced high turnover rates in its U.S. subsidiary due to a tightening labor market, impacting its ability to attract and retain key personnel [69]. - High turnover rates have been observed in the company's U.S. subsidiary, which could lead to increased operational costs and affect overall business efficiency [135]. - The company faces challenges in large-scale manufacturing, including yield and quality issues, which could affect product availability [216]. - The company has limited experience in managing clinical trials, which may lead to unforeseen delays and complications in obtaining regulatory approvals [170]. Strategic Partnerships and Collaborations - The company relies on third parties for the commercialization of its products, which exposes it to risks such as default on obligations and lack of control over marketing strategies [82][84]. - The company may need to alter its development and commercialization plans if it cannot establish collaborations or raise substantial additional capital [123]. - The company has exclusive license agreements for Talicia® in the UAE and opaganib in South Korea, but regulatory approval in these regions is uncertain [138].

Financial Performance - Record annual revenues of $85.8 million for 2021, a 33.2% increase compared to 2020[12] - In 2021, RedHill Biopharma reported net revenues of $85.8 million, a 33.3% increase from $64.4 million in 2020[50] - The company's gross profit for 2021 was $36.4 million, resulting in a gross margin of 42.0%[54] - Comprehensive loss for the year ended December 31, 2021, was $97,744 thousand, compared to $76,173 thousand in 2020, reflecting an increase of 28.5%[55] - The operating loss for 2021 was $81.1 million, an increase from $63.7 million in 2020, attributed to intensified commercial and R&D activities[17] - The operating loss for 2021 was $81.1 million, compared to $63.7 million in 2020, indicating a 27.4% increase in losses[50] Revenue Growth - Fourth quarter revenues reached $22.1 million, up from $21.6 million in Q3 2021[7] - Talicia became the most prescribed branded H. pylori therapy in the U.S., with a 25.5% increase in prescriptions in Q4 compared to Q3[26] - Movantik holds a 73% market share in the PAMORA class, with a 2.4% increase in new prescriptions in Q4 compared to Q3[23] Cash and Financing Activities - Cash balance as of December 31, 2021, was $54.2 million, up from $51.5 million as of September 30, 2021[20] - Net cash provided by financing activities for 2021 was $73.5 million, primarily from equity offerings[18] - Proceeds from the issuance of ordinary shares in 2021 amounted to $78,536 thousand, significantly higher than $23,867 thousand in 2020, marking a 228% increase[55] - The company had a net cash provided by financing activities of $73,462 thousand in 2021, a decrease from $84,370 thousand in 2020, down by 12.6%[55] - The cash balance includes restricted cash of $16 million as of December 31, 2020, which is relevant for liquidity considerations[56] Research and Development - Research and Development expenses for 2021 totaled $29.5 million, compared to $16.5 million in 2020, driven by COVID-19 program advancements[15] - Research and development expenses increased to $29.5 million in 2021, up from $16.5 million in 2020, reflecting a 78.9% rise[50] - The ongoing Phase 3 study for RHB-204 aims to evaluate efficacy and safety in adults with pulmonary NTM disease, with enrollment expected to increase as COVID-19 wanes[42] - Positive late-stage clinical data for COVID-19 therapeutics opaganib and RHB-107, with ongoing regulatory submissions[4] - The Phase 2/3 study for opaganib showed a significant 34% benefit in time to recovery for treated patients compared to placebo[38] - Discussions with regulators regarding next steps for RHB-107 are anticipated in Q2 2022[41] Asset Management - RedHill Biopharma's total assets as of December 31, 2021, were $181.2 million, slightly up from $180.2 million in 2020[52] - The company had a cash and cash equivalents balance of $29.5 million at the end of 2021, compared to $29.3 million in 2020[52] Operational Metrics - Net cash used in operating activities for 2021 was $65,047 thousand, up from $48,579 thousand in 2020, indicating a 34% increase in cash outflow[55] - The total depreciation expense for 2021 was $1,914 thousand, up from $1,710 thousand in 2020, representing an increase of 11.9%[55] - The acquisition of right-of-use assets by means of lease liabilities was $303 thousand in 2021, compared to $2,930 thousand in 2020, a decrease of 89.7%[55] - The company reported a fair value loss on financial assets at fair value through profit or loss of $5 thousand in 2021, compared to a gain of $94 thousand in 2020[55] - The company reported an increase in the allowance for deductions from revenue by $12,368 thousand in 2021, compared to $17,076 thousand in 2020, a decrease of 27.5%[55] Future Outlook - The company expects to achieve non-GAAP commercial operations profitability in 2022, despite anticipated operating losses[47]

RedHill Biopharma Ltd. (NASDAQ:RDHL) Q3 2021 Earnings Conference Call November 30, 2021 8:30 AM ET Company Participants Alexandra Okmian - Senior Business Development and IR Manager Dror Ben-Asher - CEO Guy Goldberg - Chief Business Officer Gilead Raday - COO Rob Jackson - SVP, Sales and Marketing Micha Ben-Chorin - CFO Bob Gilkin - SVP, Market Access and Trade Relations Conference Call Participants Brandon Folkes - Cantor Fitzgerald Boobalan Pachaiyappan - H.C. Wainwright David Hoang - SMBC Robert Hazlett ...

RedHill Biopharma Ltd. ("RDHL") Corporate Presentation November 2021 Forward Looking Statement This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company's securities or to participate in any investment in the Company. No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained herein. In particular, no ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) Q2 2021 Earnings Conference Call August 26, 2021 8:30 AM ET Company Participants Alexandra Okmian - Senior Business Development and Investor Relations Manager Dror Ben-Asher - Chief Executive Officer Guy Goldberg - Chief Business Officer Gilead Raday - Chief Operating Officer Rob Jackson - Senior Vice President, Sales and Marketing Micha Ben-Chorin - Chief Financial Officer Rick Scruggs - Chief Commercial Officer Adi Frish - Chief Corporate and Business Development Offic ...

RedHill Biopharma Ltd. ("RDHL") Corporate Presentation August 2021 Forward Looking Statement This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company's securities or to participate in any investment in the Company. No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained herein. In particular, no r ...